FENC
Fennec Pharmaceuticals
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
FENC Profile
Fennec Pharmaceuticals Inc.
A company that developing Sodium Thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients
Biological Technology
Invalid Date
09/13/2017
NASDAQ Stock Exchange
32
12-31
Common stock
PO Box 13628, 68 TW Alexander Drive , Research Triangle Park, NC 27709
--
Fennec Pharmaceuticals Inc., originally established as a British Columbia company under the name "Sticky" Technologies, changed its name on September 3, 2014. Fennec, together with its wholly owned subsidiaries Oxyquit Corporation (" Oxide ") and Fennec Pharmaceuticals, and a Canadian company in Canada (" CBI "), collectively referred to here as the "Company", is a biopharmaceutical company with a product in development for the treatment of cancer. The Company is a biopharmaceutical company focused on the development of sodium thiosulfate (" STS ") to prevent the toxicity of platinum poisoning in pediatric cancer patients.